Response to: 'Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?' by Erre et al
- PMID: 32424027
- DOI: 10.1136/annrheumdis-2020-217923
Response to: 'Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?' by Erre et al
Keywords: cardiovascular diseases; hydroxychloroquine; inflammation.
Conflict of interest statement
Competing interests: AHK reports grants from NIH/NIAMS and Rheumatology Research Foundation and personal fees from Exagen Diagnostics and GlaxoSmithKline. JAS reports grants from NIH/NIAID/Autoimmune Centers of Excellence, the Rheumatology Research Foundation, the Brigham Research Institute and the R. Bruce and Joan M. Mickey Research Scholar Fund as well as personal fees from Bristol-Myers Squibb, Gilead, Inova, Janssen, and Optum.
Comment on
-
Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?Ann Rheum Dis. 2021 Mar;80(3):e29. doi: 10.1136/annrheumdis-2020-217828. Epub 2020 May 18. Ann Rheum Dis. 2021. PMID: 32424028 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
